FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2099312711> ?p ?o ?g. }

• W2099312711 endingPage "1599" @default.
• W2099312711 startingPage "1589" @default.
• W2099312711 abstract "ABSTRACT Finding an effective human immunodeficiency virus type 1 (HIV-1) vaccine remains a major global health priority. In a phase I/II, placebo-controlled trial, healthy, HIV-1-negative adults were randomized to receive one of 5 vaccine regimens: LIPO-5 (combination of 5 lipopeptides) alone (250 μg), ALVAC-HIV (vCP1452) alone, or 3 groups of ALVAC-HIV (vCP1452) followed by ALVAC-HIV (vCP1452) plus LIPO-5 (250, 750, and 2,500 μg). Only 73/174 participants (42%) received all four vaccinations due to a study halt related to myelitis. There were no significant differences in systemic reactions between groups or in local reactogenicity between groups receiving ALVAC-HIV (vCP1452). Significant differences in local reactogenicity occurred between groups receiving LIPO-5 ( P ≤ 0.05). Gag and Env antibodies were undetectable by ELISA 2 weeks after the fourth vaccination for all but one recipient. Antibodies to Gag and Env were present in 32% and 24% of recipients of ALVAC-HIV (vCP1452) alone and in 47% and 35% of ALVAC-HIV (vCP1452)+LIPO recipients, respectively. Coadministration of LIPO-5 did not significantly increase the response rate compared to ALVAC-HIV (vCP1452) alone, nor was there a significant relationship between dose and antibody responses among ALVAC-HIV (vCP1452)+LIPO groups. Over 90% of study participants had no positive gamma interferon (IFN-γ) enzyme-linked immunosorbent spot assay (ELISpot) responses to any peptide pool at any time point. The study was halted due to a case of myelitis possibly related to the LIPO-5 vaccine; this case of myelitis remains an isolated event. In general, there was no appreciable cell-mediated immunity detected in response to the vaccines used in this study, and antibody responses were limited. The clinical trial is registered on ClinicalTrials.gov with registry number NCT00076063." @default.
• W2099312711 created "2016-06-24" @default.
• W2099312711 creator A5004334810 @default.
• W2099312711 creator A5004424978 @default.
• W2099312711 creator A5005368354 @default.
• W2099312711 creator A5010145313 @default.
• W2099312711 creator A5014680841 @default.
• W2099312711 creator A5017596396 @default.
• W2099312711 creator A5025150770 @default.
• W2099312711 creator A5025852667 @default.
• W2099312711 creator A5028253446 @default.
• W2099312711 creator A5029359442 @default.
• W2099312711 creator A5031000479 @default.
• W2099312711 creator A5034536696 @default.
• W2099312711 creator A5039473114 @default.
• W2099312711 creator A5049629272 @default.
• W2099312711 creator A5052639304 @default.
• W2099312711 creator A5064182369 @default.
• W2099312711 creator A5067647063 @default.
• W2099312711 creator A5075731113 @default.
• W2099312711 creator A5078714130 @default.
• W2099312711 creator A5085731242 @default.
• W2099312711 creator A5088127680 @default.
• W2099312711 creator A5091029647 @default.
• W2099312711 date "2014-09-24" @default.
• W2099312711 modified "2023-10-03" @default.
• W2099312711 title "Phase I/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime/LIPO-5 Boost in Healthy, HIV-1-Uninfected Adult Participants" @default.
• W2099312711 cites W1537342340 @default.
• W2099312711 cites W1548131894 @default.
• W2099312711 cites W1600700372 @default.
• W2099312711 cites W1610079506 @default.
• W2099312711 cites W1893500657 @default.
• W2099312711 cites W1967984729 @default.
• W2099312711 cites W1969498684 @default.
• W2099312711 cites W1980497671 @default.
• W2099312711 cites W1983194006 @default.
• W2099312711 cites W1984512389 @default.
• W2099312711 cites W1986908492 @default.
• W2099312711 cites W1989087827 @default.
• W2099312711 cites W1990626907 @default.
• W2099312711 cites W1991253838 @default.
• W2099312711 cites W1993250167 @default.
• W2099312711 cites W1994749859 @default.
• W2099312711 cites W2003913885 @default.
• W2099312711 cites W2010391664 @default.
• W2099312711 cites W2013165213 @default.
• W2099312711 cites W2044226704 @default.
• W2099312711 cites W2081066370 @default.
• W2099312711 cites W2084499948 @default.
• W2099312711 cites W2084808899 @default.
• W2099312711 cites W2090359320 @default.
• W2099312711 cites W2099067260 @default.
• W2099312711 cites W2103920597 @default.
• W2099312711 cites W2107419870 @default.
• W2099312711 cites W2108103663 @default.
• W2099312711 cites W2108868448 @default.
• W2099312711 cites W2109364135 @default.
• W2099312711 cites W2118513281 @default.
• W2099312711 cites W2127237615 @default.
• W2099312711 cites W2129550844 @default.
• W2099312711 cites W2138604744 @default.
• W2099312711 cites W2138723840 @default.
• W2099312711 cites W2143421242 @default.
• W2099312711 cites W2152048324 @default.
• W2099312711 cites W2152505869 @default.
• W2099312711 cites W2156392662 @default.
• W2099312711 cites W2620992862 @default.
• W2099312711 doi "https://doi.org/10.1128/cvi.00450-14" @default.
• W2099312711 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4248765" @default.
• W2099312711 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25253665" @default.
• W2099312711 hasPublicationYear "2014" @default.
• W2099312711 type Work @default.
• W2099312711 sameAs 2099312711 @default.
• W2099312711 citedByCount "8" @default.
• W2099312711 countsByYear W20993127112014 @default.
• W2099312711 countsByYear W20993127112015 @default.
• W2099312711 countsByYear W20993127112016 @default.
• W2099312711 countsByYear W20993127112017 @default.
• W2099312711 countsByYear W20993127112019 @default.
• W2099312711 countsByYear W20993127112020 @default.
• W2099312711 crossrefType "journal-article" @default.
• W2099312711 hasAuthorship W2099312711A5004334810 @default.
• W2099312711 hasAuthorship W2099312711A5004424978 @default.
• W2099312711 hasAuthorship W2099312711A5005368354 @default.
• W2099312711 hasAuthorship W2099312711A5010145313 @default.
• W2099312711 hasAuthorship W2099312711A5014680841 @default.
• W2099312711 hasAuthorship W2099312711A5017596396 @default.
• W2099312711 hasAuthorship W2099312711A5025150770 @default.
• W2099312711 hasAuthorship W2099312711A5025852667 @default.
• W2099312711 hasAuthorship W2099312711A5028253446 @default.
• W2099312711 hasAuthorship W2099312711A5029359442 @default.
• W2099312711 hasAuthorship W2099312711A5031000479 @default.
• W2099312711 hasAuthorship W2099312711A5034536696 @default.
• W2099312711 hasAuthorship W2099312711A5039473114 @default.
• W2099312711 hasAuthorship W2099312711A5049629272 @default.
• W2099312711 hasAuthorship W2099312711A5052639304 @default.
• W2099312711 hasAuthorship W2099312711A5064182369 @default.
• W2099312711 hasAuthorship W2099312711A5067647063 @default.

• next